Inspira Technologies Reaffirms $49.5M Binding Purchase Orders; Payments To Commence FY2026 Aligned With Regulatory And Deployment Milestones

Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today reaffirmed its previously announced binding purchase orders totaling $49.5 million and provided an update on execution timing, noting that payment activity has been structured to commence with the 2026 fiscal cycle, in alignment with immediate regulatory sequencing and phased deployment milestones.

The Company confirmed, based on representations received from its distribution partner, that the purchase orders remain in full force and effect and that the distributor intends to advance the orders toward execution during 2026. Following active coordination with regulatory authorities and institutional funding partners, the payment framework of the binding purchase orders has been structured to commence with the 2026 fiscal cycle, consistent with the Company's previously disclosed revenue recognition framework.

The updated schedule reflects regulatory sequencing, technical implementation requirements, and the coordination of institutional capital allocations supporting certain deliveries. These processes are customary for international large-scale healthcare deployments.

Inspira continues to work in active coordination with its distribution partners, regulators, and funding organizations to advance planned execution milestones and finalize delivery schedules. This alignment is designed to reduce execution risk, enhance operational visibility, and support a phased rollout across target markets.

The Company expects to provide updates in connection with upcoming execution and deployment milestones.